Medison Ventures

Medison Ventures is the corporate venture capital arm of Medison Pharma, one of the world's largest commercial partners for innovative pharmaceutical companies with operations in Israel, Canada, and Eastern Europe. Founded in 2016 by Meir Jakobsohn and headquartered in Petah Tikva, Israel, the firm focuses on in-licensing, equity investments, and scouting for breakthrough technologies in biotechnology and digital health. Investment activity is concentrated at the Series B stage in life sciences companies. The portfolio comprises approximately 10 investments across biotech, pharma, and digital health. Notable holdings include Alpha Tau Medical, an alpha particle cancer therapy company that completed a NASDAQ IPO in March 2021, along with Keros Therapeutics, Eloxx Pharmaceuticals, Apeiron Biologics, Allogene Therapeutics, Orchard Therapeutics, and ArQule. In 2019, Medison Ventures partnered with Pontifax to launch a $150 million venture debt fund providing clinical-stage life science companies with non-dilutive capital. Portfolio companies benefit from direct access to Medison Pharma's global network of pharmaceutical partners including Biogen, Vertex, Shire, BioMarin, IPSEN, Servier, PTC Therapeutics, and Daiichi-Sankyo. The fund's primary value proposition is commercial access: portfolio companies gain introductions to established pharmaceutical distributors and commercial partners through Medison Pharma's existing relationships, potentially accelerating the path from clinical development to market. The fund is currently presumed inactive with no publicly recorded recent investments, reflecting the typical life cycle of a focused corporate VC vehicle tied to its parent's strategic priorities.